Antinociceptive and Cardiorespiratory Effects of a Single Dose of Dexmedetomidine in Laboratory Mice Subjected to Craniotomy under General Anaesthesia with Isoflurane and Carprofen or Meloxicam.
Anika R SchieleInken S HenzeRegula Bettschart-WolfensbergerThomas C GentPublished in: Animals : an open access journal from MDPI (2024)
Pain refinement represents an important aspect of animal welfare in laboratory animals. Refining analgesia regimens in mice undergoing craniotomy has been sparsely investigated. Here, we sought to investigate the effect of dexmedetomidine in combination with other analgesic drugs on intraoperative anti-nociceptive effects and cardiorespiratory stability. All mice were anaesthetised with isoflurane and received local lidocaine infiltration at the surgical site. Mice were randomised into treatment groups consisting of either carprofen 5 mg kg -1 or meloxicam 5 mg kg -1 with or without dexmedetomidine 0.1 mg kg -1 administered subcutaneously. Intra-anaesthetic heart rates, breathing rates, isoflurane requirements, and arterial oxygen saturations were continuously monitored. We found that administration of dexmedetomidine significantly improved heart and breathing rate stability during two of four noxious stimuli (skin incision and whisker stimulation) compared to non-dexmedetomidine-treated mice and lowered isoflurane requirements throughout anaesthesia by 5-6%. No significant differences were found between carprofen and meloxicam. These results demonstrate that dexmedetomidine reduces nociception and provides intra-anaesthetic haemodynamic and respiratory stability in mice. In conclusion, the addition of dexmedetomidine to anaesthetic regimes for craniotomy offers a refinement over current practice for laboratory mice.
Keyphrases
- high fat diet induced
- cardiac surgery
- healthcare
- heart failure
- primary care
- randomized controlled trial
- insulin resistance
- acute kidney injury
- body composition
- mass spectrometry
- atrial fibrillation
- skeletal muscle
- chronic pain
- study protocol
- patients undergoing
- metabolic syndrome
- open label
- combination therapy
- atomic force microscopy
- newly diagnosed